Drug Profile

Marstacimab - Pfizer

Alternative Names: HYMPAVZI; Hympavzi; Marstacimab-hncq - Pfizer; PF-06741086; PF-6741086

Latest Information Update: 11 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pfizer
Class Antihaemorrhagics; Coagulants; Monoclonal antibodies
Mechanism of Action Lipoprotein-associated coagulation inhibitor inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Haemophilia B; Haemophilia A
New Molecular Entity Yes

Highest Development Phases

Registered Haemophilia A; Haemophilia B

Most Recent Events

06 Feb 2026 Preregistration for Haemophilia A (In children) in USA (SC)
06 Feb 2026 Preregistration for Haemophilia B (In children) in USA (SC)
06 Feb 2026 FDA assigns PDUFA action date of second half of 2026 for marstacimab for Hemophilia A and Hemophilia B

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com